This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Munn, D. H. Articles by Cheung, N.-K. V. Search for Related Content PubMed PubMed Citation Articles by Munn, D. H. Articles by Cheung, N.-K. V.

Interleukin-2 Enhancement of Monoclonal Antibody-mediated Cellular Cytotoxicity against Human Melanoma¹

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, and Case Western Reserve University, Ireland Cancer Center, Cleveland, Ohio 44106

Disialoganglioside G_D2 is present on human neuroblastoma and melanoma cells. 3F8 is a murine IgG3 monoclonal antibody specific for G_D2, which has shown antitumor effects in patients in preliminary clinical studies. Since antibody mediated cellular cytotoxicity (ADCC) was one of the likely mechanisms producing these observed tumor regressions, the current study was carried out to investigate the activation of ADCC by interleukin-2 (IL-2). ADCC (against human neuroblastoma and melanoma cell lines in vitro) mediated by normal human peripheral blood lymphocytes was increased 100 to 330% after preincubation with IL-2. At limiting concentrations of 3F8 antibody (10 to 100 times less than the amount required by unactivated peripheral blood lymphocytes), activated peripheral blood lymphocytes still mediated efficient ADCC. Activation of ADCC was detected earlier than lymphokine activated killer cell (LAK) activity, required less IL-2 for optimum induction (50 versus 1000 units/ml), and was of equal or greater absolute magnitude (+10 to +200%) against the cell lines tested. ADCC and LAK were independent and additive when measured against the same cell line. The precursor cells for both LAK and activated ADCC bore IgG Fc receptors, but by day 4 of culture with IL-2 much of the LAK activity resided in the Fc negative, Leu11 negative population, and did not mediate ADCC. IL-2 activated ADCC may be of value alone or in conjunction with LAK cells in the therapy of tumors which bind the antibody 3F8.

¹ Supported in part by grants ACS-RD-22-86 and ACS-CDA-4-85 from the American Cancer Society, CA-39320 from the National Cancer Institute, and funds from the Ireland Cancer Center, Cleveland, OH. Part of this work has been presented at the 1987 annual meeting of the American Association for Cancer Research.

² To whom requests for reprints should be addressed, at the Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.

Received 6/ 8/87. Revised 9/18/87. Accepted 9/23/87.